A paper published by the National Bureau of Economic Research examines the economic impact of pharmacogenomic testing.
A study at the Public Library of Science finds that use of pharmacogenomics in managing drug regimens can help reduce readmissions and ER use.
The cost of whole genome sequencing is coming down, but cost, reproducibility, translation and process issues make its routine use for clinical practice unlikely without further refinement and knowledge growth.
An article in Nature describes a study of over 1000 individual genomes to identify variation. This is an important step in the continuing evolution of personalized medicine, which is proving to take longer and be more complex that may have initially been imagined.
Fall looms and brings the football season. Our Potpourri scores with nutritious bites of health information, including getting more genetic data into medical records, giving doctors price lists, the value of HIEs, reducing hospital costs, medication continuation after hospitalization and use of episode-based payments.
The FDA issues a draft guidance on the use of clinical pharmacogenomics, in particular the gathering of relevant pharmacogenomic data in early drug development studies.
The year wears on, winter hopefully draws to a close, and our Potpourri provides nutritious sustenance, this week featuring comparative effectiveness research and personalized medicine, two surveys on hospital progress in implementing EHRs, a patient-centered vision of HIT, the validity of care guidelines, and the use of clinical decision support to control inappropriate imaging.
One interesting aspect of personalized medicine is the widespread ability of consumers to purchase somewhat inexpensive genome wide scanning for disease risk. New research evaluating the potential benefits or harms of these DTC tests finds not much impact either way.